176 related articles for article (PubMed ID: 35468582)
21. Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases.
Rapino C; Tortolani D; Scipioni L; Maccarrone M
Curr Neuropharmacol; 2018; 16(7):959-970. PubMed ID: 28738764
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid receptors in the inflammatory cells of canine atopic dermatitis.
Chiocchetti R; Salamanca G; De Silva M; Gobbo F; Aspidi F; Cunha RZ; Galiazzo G; Tagliavia C; Sarli G; Morini M
Front Vet Sci; 2022; 9():987132. PubMed ID: 36187821
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.
Dao M; François H
Front Endocrinol (Lausanne); 2021; 12():720734. PubMed ID: 34305821
[TBL] [Abstract][Full Text] [Related]
24. Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB
Ferrisi R; Ceni C; Bertini S; Macchia M; Manera C; Gado F
Pharmacol Res; 2021 Aug; 170():105607. PubMed ID: 34089867
[TBL] [Abstract][Full Text] [Related]
25. Interaction between Cannabinoid Type 1 and Type 2 Receptors in the Modulation of Subventricular Zone and Dentate Gyrus Neurogenesis.
Rodrigues RS; Ribeiro FF; Ferreira F; Vaz SH; Sebastião AM; Xapelli S
Front Pharmacol; 2017; 8():516. PubMed ID: 28848435
[TBL] [Abstract][Full Text] [Related]
26. Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth.
Van Dross R; Soliman E; Jha S; Johnson T; Mukhopadhyay S
Life Sci; 2013 Mar; 92(8-9):463-6. PubMed ID: 23069587
[TBL] [Abstract][Full Text] [Related]
27. Cannabinoid receptors and TRPA1 on neuroprotection in a model of retinal ischemia.
Araújo DSM; Miya-Coreixas VS; Pandolfo P; Calaza KC
Exp Eye Res; 2017 Jan; 154():116-125. PubMed ID: 27876485
[TBL] [Abstract][Full Text] [Related]
28. The endocannabinoid system in gp120-mediated insults and HIV-associated dementia.
Bari M; Rapino C; Mozetic P; Maccarrone M
Exp Neurol; 2010 Jul; 224(1):74-84. PubMed ID: 20353779
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina.
Cécyre B; Thomas S; Ptito M; Casanova C; Bouchard JF
Naunyn Schmiedebergs Arch Pharmacol; 2014 Feb; 387(2):175-84. PubMed ID: 24185999
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System.
Zou S; Kumar U
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29533978
[TBL] [Abstract][Full Text] [Related]
31. The synthetic cannabinoids menace: a review of health risks and toxicity.
Alzu'bi A; Almahasneh F; Khasawneh R; Abu-El-Rub E; Baker WB; Al-Zoubi RM
Eur J Med Res; 2024 Jan; 29(1):49. PubMed ID: 38216984
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues.
Stamer WD; Golightly SF; Hosohata Y; Ryan EP; Porter AC; Varga E; Noecker RJ; Felder CC; Yamamura HI
Eur J Pharmacol; 2001 Nov; 431(3):277-86. PubMed ID: 11730719
[TBL] [Abstract][Full Text] [Related]
33. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.
Nucci C; Bari M; Spanò A; Corasaniti M; Bagetta G; Maccarrone M; Morrone LA
Prog Brain Res; 2008; 173():451-64. PubMed ID: 18929127
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca
Xia KK; Shen JX; Huang ZB; Song HM; Gao M; Chen DJ; Zhang SJ; Wu J
Acta Pharmacol Sin; 2019 Mar; 40(3):410-417. PubMed ID: 30202013
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS.
Hermes DJ; Xu C; Poklis JL; Niphakis MJ; Cravatt BF; Mackie K; Lichtman AH; Ignatowska-Jankowska BM; Fitting S
Neuropharmacology; 2018 Oct; 141():55-65. PubMed ID: 30114402
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid type 2 receptors mediate a cell type-specific self-inhibition in cortical neurons.
Stumpf A; Parthier D; Sammons RP; Stempel AV; Breustedt J; Rost BR; Schmitz D
Neuropharmacology; 2018 Sep; 139():217-225. PubMed ID: 30025920
[TBL] [Abstract][Full Text] [Related]
37. The Endocannabinoid System as a Therapeutic Target in Diabetic Peripheral Neuropathic Pain: A Review.
Bagher AM
J Microsc Ultrastruct; 2022; 10(2):47-54. PubMed ID: 35832317
[TBL] [Abstract][Full Text] [Related]
38. Blockade of the endovanilloid receptor, TRPV1, and of the endocannabinoid enzyme, FAAH, within the nucleus accumbens shell elicits anxiolytic-like effects in male rats.
Pardo-García TR; Yusif-Rodriguez N; Yudowski G; Maldonado-Vlaar CS
Neurosci Lett; 2020 Jul; 732():135023. PubMed ID: 32422166
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.
Brennecke B; Gazzi T; Atz K; Fingerle J; Kuner P; Schindler T; Weck G; Nazaré M; Grether U
Pharm Pat Anal; 2021 May; 10(3):111-163. PubMed ID: 34111979
[TBL] [Abstract][Full Text] [Related]
40. Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system.
Chicca A; Arena C; Bertini S; Gado F; Ciaglia E; Abate M; Digiacomo M; Lapillo M; Poli G; Bifulco M; Macchia M; Tuccinardi T; Gertsch J; Manera C
Eur J Med Chem; 2018 Jun; 154():155-171. PubMed ID: 29793210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
